<DOC>
	<DOC>NCT02217150</DOC>
	<brief_summary>Prospective clinical series to gather post tumor ablation clinical outcomes from subjects with painful spinal metastases following targeted radiofrequency ablation (t-RFA) treatment with the STAR™ Tumor Ablation System.</brief_summary>
	<brief_title>The STAR Prospective Clinical Series</brief_title>
	<detailed_description />
	<criteria>The STAR™ Tumor Ablation System is indicated for palliative treatment in spinal procedures by ablation of metastatic malignant lesions in a vertebral body. The device is contraindicated in subjects with heart pacemakers, or other electronic device implants. The device is contraindicated in vertebral body levels C17.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>